To my mind, OpenAI and Sam Altman committed the original AI sin, debuting ChatGPT to the public, following the platform-era assumption that a first mover could blitzscale consumer usage, establishing monopoly or duopoly pricing power. This neglected that consumer usage wouldn't prove adequately monetizable and model-capability leads weren't sustainable amidst an arms race. If instead, they'd started by targeting high-value enterprise use cases across sectors, they'd have had a CAPEX path more in line with an ROI path, a better chance of entrenching service loyalty, and less risk overhang, whether existential, political, or logistical.
Healthcare exemplifies that squandered opportunity. Recent survey results from Bessemer: "In 2025, 84% of executives expected Gen AI to transform clinical treatment decisions within 3 to 5 years. Just a year later, 71% say it already has. Healthcare AI ROI arrived 2x as fast and at a higher level than expected. Buyers projected ~24 months, and realized it in ~12, averaging 3.5x, exceeding expectations in ~40% of use cases. 54% see material ROI inside the first year."
I did a deep-dive on the healthcare AI opportunity in my July report on "The Medical Innovation Inflection" (
"We see compelling reason to doubt AI’s ability to deliver transformational change at the scale and on the timeline the market currently expects across sectors. We do not have the same skepticism about the impact it will have on healthcare. Yes, healthcare has long lagged other sectors in technological transformation, held back by a combination of bureaucracy, profit seeking, personal privacy concerns, and the life-and-death consequences of misguided implementation. Those issues are already dragging on and will continue to drag on AI integration in healthcare. However, we also see AI’s strengths as so obviously well-matched to so many existing healthcare shortcomings, its impact can still be game-changing even if constrained.
Study after study has shown AI’s ability to assist physicians in coming to more accurate diagnoses. For context, each year, there are more than 12m “serious diagnostic errors” just in the US, costing the US health system an estimated $100b annually. Meanwhile, AI has already transformed medical devices. The FDA has cleared more than 1,300 medical AI devices since 2015, with 331 cleared in 2025 alone. It is also transforming drug discovery. In total, there are 173 AI-originated drug programs currently in clinical development. And finally, AI is altering how care is delivered. According to survey results released in March, roughly 80% of physicians now use AI professionally. AI is reducing the administrative burden on healthcare workers, allowing more time to care for patients."
Chart link:
もっと見る